Zobrazeno 1 - 10
of 33
pro vyhledávání: '"Floris C, Loeff"'
Autor:
Sander W Tas, Michael T Nurmohamed, Gertjan Wolbink, Martijn Gerritsen, Erik H Vogelzang, Laura Boekel, Femke Hooijberg, Yaëlle R Besten, Maureen Leeuw, Sadaf Atiqi, Maurice Steenhuis, Sofie Keijzer, Jim Keijser, Floris C Loeff
Publikováno v:
RMD Open, Vol 10, Iss 2 (2024)
Background During the COVID-19 pandemic, we developed a digital research platform to longitudinally investigate COVID-19-related outcomes in patients with rheumatic diseases and healthy controls. We used home finger-prick testing in order to collect
Externí odkaz:
https://doaj.org/article/ea46065c1bc047e99e8e45a577306560
Autor:
Angela L. Bosma, Louise A. A. Gerbens, Hajar El Khattabi, Floris C. Loeff, Michael Duckworth, Richard T. Woolf, Theo Rispens, Catherine H. Smith, Phyllis I. Spuls
Publikováno v:
Journal of Dermatological Treatment, Vol 34, Iss 1 (2023)
Background Dupilumab is prescribed in one dosage across adult atopic dermatitis patients. Differences in drug exposure may explain variation in treatment response. Objective Investigating the clinical relevance of dupilumab serum concentration in ato
Externí odkaz:
https://doaj.org/article/a39c861adb6940adad969c18ee931271
Autor:
Teresa Tsakok, Jake Saklatvala, Theo Rispens, Floris C. Loeff, Annick de Vries, Michael H. Allen, Ines A. Barbosa, David Baudry, Tejus Dasandi, Michael Duckworth, Freya Meynell, Alice Russell, Anna Chapman, Sandy McBride, Kevin McKenna, Gayathri Perera, Helen Ramsay, Raakhee Ramesh, Kathleen Sands, Alexa Shipman, the Biomarkers of Systemic Treatment Outcomes in Psoriasis (BSTOP) Study Group, A. David Burden, Christopher E.M. Griffiths, Nick J. Reynolds, Richard B. Warren, Satveer Mahil, Jonathan Barker, Nick Dand, Catherine Smith, Michael A. Simpson
Publikováno v:
JCI Insight, Vol 8, Iss 4 (2023)
Targeted biologic therapies can elicit an undesirable host immune response characterized by the development of antidrug antibodies (ADA), an important cause of treatment failure. The most widely used biologic across immune-mediated diseases is adalim
Externí odkaz:
https://doaj.org/article/b7bce9e049e346049f02cc279904382b
Autor:
Fenna de Vries, Adrianus A. J. Smit, Gertjan Wolbink, Annick de Vries, Floris C. Loeff, Eric J. F. Franssen
Publikováno v:
Frontiers in Oncology, Vol 12 (2023)
BackgroundPembrolizumab is a well-tolerated biologic agent with a potentially stable and durable anti-tumor response. Unfortunately, discontinuation of therapy can occur as a consequence of immune-related adverse effects (irAEs). These irAEs appear i
Externí odkaz:
https://doaj.org/article/80f9f5ef5d7443cb95508f45902e8801
Autor:
Erin H. Smeijsters, Kim C. M. van der Elst, Amy Visch, Camiel Göbel, Floris C. Loeff, Theo Rispens, Alwin D. R. Huitema, Matthijs van Luin, Mohsin El Amrani
Publikováno v:
Pharmaceutics, Vol 15, Iss 5, p 1477 (2023)
Monoclonal antibodies (mAbs), such as infliximab, are important treatment options for different diseases. Immunogenicity is a major risk, resulting in anti-drug antibodies (ADAs), being associated with adverse events and loss of response, influencing
Externí odkaz:
https://doaj.org/article/17e81377605e42de912eb2b322fe36bf
Autor:
Ronald F van Vollenhoven, Sander W Tas, Taco W Kuijpers, Maarten Boers, Michael T Nurmohamed, Gertjan Wolbink, Irene E van der Horst-Bruinsma, Theo Rispens, Willem Lems, Alexandre Voskuyl, Carla A Wijbrandts, S Marieke van Ham, Martijn Gerritsen, Erik H Vogelzang, Luuk Wieske, Laura Boekel, Femke Hooijberg, Yaëlle R Besten, Maureen Leeuw, Sadaf Atiqi, C Krieckaert, Bas Dijkshoorn, Siham Bakhlakh, Juliette J Crooijmans, Filip Eftimov, Laura Y Kummer, PJ Koos van Dam, Eileen W Stalman, Maurice Steenhuis, Sofie Keijzer, Olvi Cristianawati, Jim Keijser, Floris C Loeff
Publikováno v:
RMD Open, Vol 8, Iss 1 (2022)
Externí odkaz:
https://doaj.org/article/c31dbe2993a2456ab42dc303970a81d9
Autor:
Shan Pan, Teresa Tsakok, Nick Dand, Dagan O. Lonsdale, Floris C. Loeff, Karien Bloem, Annick deVries, David Baudry, Michael Duckworth, Satveer Mahil, Angela Pushpa‐Rajah, Alice Russell, Ali Alsharqi, Gabrielle Becher, Ruth Murphy, Shyamal Wahie, Andrew Wright, Christopher E.M. Griffiths, Nick J. Reynolds, Jonathan Barker, Richard B. Warren, A. David Burden, Theo Rispens, Joseph F. Standing, Catherine H. Smith, on behalf of the BADBIR Study Group, the BSTOP Study Group, the PSORT Consortium
Publikováno v:
Clinical and Translational Science, Vol 13, Iss 2, Pp 400-409 (2020)
Variation in response to biologic therapy for inflammatory diseases, such as psoriasis, is partly driven by variation in drug exposure. Real‐world psoriasis data were used to develop a pharmacokinetic/pharmacodynamic (PK/PD) model for the first‐l
Externí odkaz:
https://doaj.org/article/619cb5f9e3a54af0aff4b70a0b891c13
Autor:
Merve Sivridaş, Rob H. Creemers, Dennis R. Wong, Paul J. Boekema, Tessa E. H. Römkens, Lennard P. L. Gilissen, Adriaan A. van Bodegraven, Floris C. Loeff, Theo Rispens, Luc J. J. Derijks
Publikováno v:
Pharmaceutics, Vol 15, Iss 3, p 972 (2023)
There are limited data on therapeutic drug monitoring (TDM) in inflammatory bowel disease (IBD) patients treated with vedolizumab (VDZ). Although an exposure–response relation has been demonstrated in the post-induction phase, this relationship is
Externí odkaz:
https://doaj.org/article/935e6f04083545d584795100813406b1
Publikováno v:
Frontiers in Immunology, Vol 11 (2020)
Tumor necrosis factor inhibitors (TNFi) have significantly improved treatment outcome of rheumatic diseases since their incorporation into treatment protocols two decades ago. Nevertheless, a substantial fraction of patients experiences either primar
Externí odkaz:
https://doaj.org/article/74af1e065ef8423a9f382ebacca3c57e
Autor:
Christina Großerichter-Wagener, Dorien Kos, Astrid van Leeuwen, Lisanne Dijk, Jorn Jeremiasse, Floris C. Loeff, Theo Rispens
Publikováno v:
mAbs, Vol 12, Iss 1 (2020)
Antibody formation to human(ized) therapeutic antibodies in humans is highly skewed toward anti-idiotype responses, probably because the idiotype is the only ‘foreign’ part of the antibody molecule. Here, we analyzed antibody responses to F(ab’
Externí odkaz:
https://doaj.org/article/d22a66eaf78042a1b8075f2ff77e4d71